This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechnology: Archive
Can Eli Lilly's Oncology Portfolio Drive Growth Beyond GLP-1 Drugs?
by Ahan Chakraborty
LLY's oncology revenues rise 11% in the first half of 2026, as newer drugs gain traction and pipeline assets add growth opportunities.
LLYNegative Net Change AZNNegative Net Change PFENegative Net Change MRKNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
JAZZ Secures FDA Nod for Expanded Use of Ziihera in Gastric Cancer
by Zacks Equity Research
Jazz Pharmaceuticals' Ziihera wins FDA approval for first-line HER2-positive GEA, expanding its market and showing strong progression-free and survival benefits.
JAZZNegative Net Change ACIUNegative Net Change ZYMENegative Net Change AMRXNegative Net Change
biotechnology
SYRE Stock Sinks After Mixed SKYWAY Study Data in Rheumatoid Arthritis
by Zacks Equity Research
Spyre's SPY072 shows activity in RA, but a smaller-than-expected benefit shifts its focus toward broader autoimmune uses and combinations.
SYRENegative Net Change ACIUNegative Net Change AMRXNegative Net Change PGENNegative Net Change
biotechnology
5 Biotech Stocks Worth Adding to Your Portfolio Now
by Ekta Bagri
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, RGEN, IOVA, ARQT and PGEN in this volatile sector.
HALONegative Net Change RGENNegative Net Change IOVANegative Net Change PGENNegative Net Change ARQTNegative Net Change
biotechnology biotechs cancer medical pharmaceuticals
Strategic Education (STRA) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
STRANegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Pulmonx Corporation (LUNG) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
LUNGNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
NVO vs. GPCR: Which Obesity Stock Is the Better Buy Right Now?
by Ahan Chakraborty
Novo Nordisk and Structure Therapeutics are taking different paths in the obesity market, from a global GLP-1 leader to a clinical-stage challenger with oral therapies.
NVONegative Net Change GPCRNegative Net Change LLYNegative Net Change
biotechnology biotechs medical pharmaceuticals
PFE vs BMY: Which Large Oncology Drugmaker Is a Better Stock Now?
by Zacks Equity Research
PFE and BMY both boast strong oncology portfolios, but Pfizer's valuation and broader diversification make it the more attractive pick now.
BMYNegative Net Change PFENegative Net Change
biotechnology biotechs medical pharmaceuticals
EC Approves Label Expansion of GILD's Trodelvy in First-line Metastatic TNBC
by Zacks Equity Research
Trodelvy's latest EU approval with Keytruda expands its first-line metastatic TNBC use, strengthening Gilead???s oncology growth opportunity.
GILDNegative Net Change GSKPositive Net Change MRKNegative Net Change
biotechnology biotechs medical pharmaceuticals
RGNX Stock Slumps 25% on FDA Clinical Hold for RGX-121 Gene Therapy
by Zacks Equity Research
REGENXBIO stock plunges 25% after the FDA places a clinical hold on RGX-121 for MPS II, following asymptomatic spine MRI findings in five participants.
RGNXPositive Net Change ABBVNegative Net Change ACIUNegative Net Change AMRXNegative Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals